President Cyril Ramaphosa and Health Minister Dr. Aaron Motsoaledi launched the long-acting HIV prevention injectable Lenacapavir at Lilian Ngoyi Stadium in Mpumalanga, South Africa [1].
The introduction of this medication represents a significant shift in preventative care for a nation facing one of the highest burdens of HIV globally. By reducing the frequency of doses required for protection, the government aims to increase adherence and accessibility for at-risk populations.
Lenacapavir is administered via injection twice a year [1]. Each single dose offers six months of continuous HIV protection [1]. This long-acting approach removes the need for daily oral medication, which has historically posed challenges for consistent use among many patients.
The rollout comes as South Africa manages a crisis where approximately eight million people are living with HIV [1]. The government intends for the injectable to serve as a primary tool in reducing new infections across the country.
While the launch took place in Mpumalanga, some reports have caused confusion regarding the location of the rollout, with one source incorrectly placing the event in Nigeria [1, 2]. However, official proceedings were held at the Lilian Ngoyi Stadium [1].
Health officials said the goal is to provide a sustainable, long-term solution for prevention. The focus remains on integrating this new medical tool into the existing public health infrastructure to ensure that those most in need can access the injections without frequent clinic visits.
“Lenacapavir is administered via injection twice a year”
The transition from daily pills to a biannual injection addresses 'pill fatigue' and the stigma associated with daily medication. If successful, this rollout could significantly lower the rate of new HIV infections in South Africa by removing the behavioral barriers to consistent prophylaxis.
